• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Novo Nordisk’s GLP-1 sales surge, but Q2 earnings disappoint

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 07, 2024 at 12:03: PM
via Novo’s operating profit increased by 8% at CER, though it was adversely impacted by the impairment loss related to ocedurenone of 5.7 billion DKK.

article source
 

<



Similar threads

cafead
As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them
Replies
0
Views
23
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Replies
0
Views
70
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GLP-1s Like Novo Nordisk’s Ozempic Do Not Increase Thyroid Cancer Risk: Study
Replies
0
Views
254
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China
Replies
0
Views
130
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk, Eli Lilly face injury lawsuit from user of popular GLP-1 medicines
Replies
0
Views
175
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote